Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10908214 | 0.90 | FFAR1 (0.54) | ALDH1A1FFAR1ACHECYP2C19KMT2A | |
| SCHEMBL15614683 | 0.86 | CYP2C19 (0.59) | ALDH1A1ACHECYP2C19CYP1A2MEN1 | |
| SCHEMBL18228832 | 0.85 | HTR2A (0.57) | ALDH1A1FFAR1MEN1KMT2AHTR2A | |
| SCHEMBL29883209 | 0.85 | CACNA2D1 (0.55) | ALDH1A1FFAR1ACHECYP2C19MEN1 | |
| SCHEMBL9155517 | 0.85 | CACNA2D1 (0.55) | ALDH1A1FFAR1ACHECYP2C19MEN1 | |
| SCHEMBL10974823 | 0.81 | FFAR1 (0.55) | ALDH1A1FFAR1ACHECYP2C19CYP1A2 | |
| SCHEMBL1979497 | 0.81 | FFAR1 (0.51) | ALDH1A1FFAR1CYP2C19CYP1A2MEN1 | |
| SCHEMBL1979348 | 0.81 | KMT2A (0.58) | FFAR1CYP2C19CYP1A2MEN1KMT2A | |
| SCHEMBL29157155 | 0.80 | FFAR1 (0.46) | FFAR1ACHECYP2C19MEN1KMT2A | |
| SCHEMBL369941 | 0.79 | KMT2A (0.49) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, GPR119, ADRB1 | ALDH1A1 132/4885FFAR1 14/4885ACHE 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.